

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19269 A1

- (51) International Patent Classification⁷: **A61B 18/18** (72) Inventor: **KEANE, David**; 51 Woodside Avenue, Wellesley, MA 02462 (US).
- (21) International Application Number: **PCT/US00/24835** (74) Agents: **GEARY, William, C., III** et al.; Nutter, McClen-
nen & Fish, LLP, One International Place, Boston, MA
02110-2699 (US).
- (22) International Filing Date:
11 September 2000 (11.09.2000)
- (25) Filing Language: English (81) Designated States (*national*): CA, JP.
- (26) Publication Language: English (84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).
- (30) Priority Data:
09/396,959 15 September 1999 (15.09.1999) US
09/539,056 30 March 2000 (30.03.2000) US
- (71) Applicant: **THE GENERAL HOSPITAL CORPORATION d.b.a MASSACHUSETTS GENERAL HOSPITAL** [US/US]; 55 Fruit Street, Boston, MA 02114 (US).
- Published:**
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PULMONARY VEIN ABLATION STENT AND METHOD



(57) Abstract: A system for treating atrial fibrillation includes a stent (10) and delivery catheter (5) for carrying the stent (10) to a treatment site. The stent is self-expanding, for example, being formed of a shape memory alloy, and is configured to lodge against the interior wall of a pulmonary vein. The stent (10) may be formed as a loop (34), helix (32), progressively wound helix or other suitable shape, and in one embodiment has an exposed proximal portion including an ablation region that contacts and subtends a circumference of the vein, or contacts endocardial wall tissue along a circumferential path at the ostium. The proximal portion (18) is attached to an energy delivery line in the catheter (5) to energize the stent (10) and ablate tissue in the circumferential region, forming a lesion to block conduction across the ostium or preventing trigger signals originating in the pulmonary vein from initiating or sustaining fibrillation in the atrium. The stent (10) also provides support for the vessel wall, reducing the likelihood of developing pulmonary vein stenosis. The stent (10) may also be deployed without concurrent or concomitant ablation, to prevent or treat primary or secondary pulmonary vein stenosis.

WO 01/19269 A1

PULMONARY VEIN ABLATION STENT AND METHOD

BACKGROUND OF THE INVENTION

The present invention relates to cardiac treatment, and particularly relates to methods and devices for treating cardiac conditions such as atrial fibrillation.

5 Atrial fibrillation is a common cardiac rhythm disorder which can affect the quality of a patient's life and may be associated with significant morbidity. Atrial fibrillation is characterized by a rapid disorganized rhythm of the upper chambers of the heart (the atria). Instead of a single wavefront of electrical activation during regular rhythm, atria
10 fibrillation consists of multiple coexistent wavefronts with random reentry. The condition may arise following cardiac surgery, or after infection. Its etiology is varied and has even been hypothesized in some cases to have a genetic component. While medication is effective to control fibrillation in some patients, endocardial ablation or surgical intervention is often necessary for effective treatment.

15 Endovascular approaches may be used to create lesions using an ablation catheter to block intraatrial conduction. Surgical procedures such as Cox's maze have been used to address the problem. This procedure creates surgical lines to compartmentalize the tissue of the cardiac wall into a plurality of regions which are each too small to support a depolarization/repolarization cycle.

20 The results of early clinical trials of ablation to treat atrial fibrillation indicate that in a significant proportion of patients with atrial fibrillation, the cause lies in the pulmonary veins. The pulmonary veins contain a sleeve of heart muscle in their proximal extension from the left atrium, and episodes of atrial fibrillation are often triggered by rapidly discharging foci in this region of the pulmonary veins. Such rapidly discharging foci may be located as far as several centimeters up a pulmonary vein. Catheter ablation of
25 focal triggers in the pulmonary veins has been reported to prevent the recurrence of atrial fibrillation in some patients.

30 This suggests that rather than attempting to localize sparsely scattered groups of rapidly depolarizing cells, these triggers may be blocked by creating a circumferential lesion at the os of the pulmonary vein, thus simply electrically isolating the entire pulmonary vein from the atrium. Indeed, where a trigger from a venous focus is necessary

to initiate or maintain fibrillation, such a circumferential lesion may be all that is required for successful ablation treatment in a significant proportion of patients.

However, clinical case reports indicate that the application of RF energy within a pulmonary vein may be associated with a risk of developing stenosis subsequent to the ablation. This stenosis can result in pulmonary hypertension, requiring a follow-up pulmonary vein balloon angioplasty or other intervention for its resolution.

Thus, treatment of atrial fibrillation in this set of patients by extracardiac ablation may require close follow up and secondary treatment to avoid complications.

It would therefore be desirable to provide a non-surgical treatment for atrial fibrillation.

It would further be desirable to provide a non-surgical treatment without stenotic complications.

SUMMARY OF THE INVENTION

This is achieved in accordance with the present invention by inserting a self-expanding stent configured to lodge in a pulmonary vein and having an exposed conductive region forming a loop. The stent is delivered via a flexibly deflectable endovascular delivery catheter, which is inserted in a femoral vein and follows a transseptal path to carry the stent in a compact form through the left atrium and deliver it to the pulmonary vein. The stent is then at least partially released or ejected from the catheter and expands into position such that the exposed conductive loop contacts the pulmonary vein around the vessel interior circumference. The stent remains electrically attached to the catheter, which carries an energy supply line, such as an RF cable or other energy conductor, or a cryogenic system, for supplying ablation energy or cryotherapy to the stent. This line is then energized to form a lesion in that portion of the vessel contacting the exposed loop, after which the stent is detached from the catheter and remains positioned in the vein to maintain vessel patency. In alternative embodiments, the ablation portion may include a proximal loop sized and positioned to contact the posterior left atrial wall outside the os of the pulmonary vein and to ablate a blocking lesion in the wall.

In one embodiment, the stent has the shape of a simple wire or ribbon helix with one or more full circumferential turns or windings of the helix exposed to operate as an ablation electrode and form the ablation lesion. The remaining turns of the helix may be covered by electrical insulation, so that the ablation energy is selectively placed in a circumferential line or band at the os. In another embodiment, the coil forms a closed loop which zig-zags around a ring-like contour such that when expanded it subtends a circumferential cylindrical band around the axis of the vessel. In yet another embodiment, the stent has a proximal coil or loop that is larger than, or expandable to be larger than, the distal portion of its body, which may be formed of coils, loops or other known stenting structures. The proximal portion lies against the endocardial surface of the posterior left atrium, while the distal portion anchors the stent within the pulmonary vein. In this embodiment the proximal portion may be configured to ablate a circumferential lesion outside the pulmonary vein, which may further reduce the risk of inducing pulmonary vein stenosis. Other known stent shapes and structures may be used, which contain, or which are augmented to contain, or which are selectively insulated so as to expose or leave exposed, a conductive loop positioned for defining a blocking lesion at the vessel entrance.

The stent may also be used to prevent or treat pulmonary vein stenosis following ablation of the pulmonary vein or adjacent atrium by any other form of ablative energy system, such as cryotherapy, laser, ultrasound, microwave or rf energy treatment, among others. In that case, the proximal portion expands to a size larger than the pulmonary vein os.

The stent may be formed of a material such as a shape memory alloy (e.g., nitinol wire or a titanium or other such alloy), or such as a superelastic alloy. The wire or structural material of the stent may, moreover, be of light construction since it need only possess sufficient structural resilient force to counteract venous recoil and prevent stenosis.

In general, applicant contemplates that the ablation energy utilized in a stent of the present invention may take several forms. A radio-frequency signal may be applied to an exposed conductor, and optionally irrigation through the conductor or via an ancillary structure, may be provided to cool the surface, vary electrical conduction or otherwise modulate the lesion characteristics. Alternatively, with suitable stent and delivery

structures, ablation may be effected by laser, ultrasound, microwave or cryothermal ablation. For clarity of exposition below, however, the illustrated structures shall be generally described and referred to simply as rf or electrical ablation structures.

Advantageously, the catheter need carry no balloon or other expansion mechanism, and does not actively effect stent expansion, so the delivery system can be quite small. It thus avoids the risk of balloon injury to the venous wall, and avoids the transient pulmonary vein occlusion that occurs with balloon delivery systems. Once deployed, however, the stent may be further expanded, or an anchor mechanism may be set, by balloon inflation if necessary. The electrical connection between catheter and stent may be effected by a fusible link, by a removable ribbon or wire attached with conductive adhesive, or by temporary capture of the stent between, or electrical contact with, conductive components of the stent delivery mechanism.

Once placed, the stent functions as a wall support in the pulmonary vein and thus may reduce wall stress and stretching that occurs, for example, in the presence of left ventricular diastolic dysfunction, mitral stenosis or regurgitation, or other conditions of left atrial hypertension. This further therapeutic support is therefore believed to contribute generally to the integrity of the vessel wall and the health of the subtended lung, and to remove a potential contribution to the development of automaticity in the pulmonary vein myocytes.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the invention will be understood from the description below taken in conjunction with the illustrative drawings of representative embodiments, wherein:

Figure 1 is a flow chart illustrating steps of the treatment procedure of the present invention;

Figure 1A illustrates catheter placement of the ablation stent in a pulmonary vein;

Figure 2 illustrates a pulmonary vein ablation stent delivery catheter in accordance with one embodiment of the invention;

Figure 3 illustrates a second embodiment of the pulmonary vein ablation stent;

Figure 4, and 4A-C illustrate a third embodiment of the stent and a method of deployment; and

Figure 4D illustrates another stent embodiment.

5 DETAILED DESCRIPTION

Figure 1 illustrates basic steps in a method in accordance with the present invention. The method is broadly applicable to block occult trigger signals from reaching the cardiac wall and is applied when one has, as an initial matter, determined that an arrhythmia is initiated or sustained by triggering signals located in a pulmonary vein. In accordance with the method, a special catheter configured to deliver a stent is employed to
10 access the pulmonary vein. In a typical procedure, the catheter is inserted percutaneously to the femoral vein and is navigated along the venous system to the right atrium of the heart, through the atrial septum and into the left atrium. In general, the catheter may be of any suitable design which is sufficiently steerable or deflectable for transseptal access and use. The insertion procedure may involve a preliminary procedure for inserting a guide
15 wire, penetrating the atrial septum and positioning the guide wire to guide the catheter to the intended locus. The catheter is then guided, for example to one of the pulmonary veins in the left atrium, and, with its tip positioned just past the ostium, is actuated to deploy the stent carried in the catheter tip at a proximal site within the pulmonary vein. Ablation
20 energy is then provided to form a blocking lesion.

Figure 2 illustrates in schematic form the stent and the catheter tip of one system in accordance with the present invention. As shown, the stent 10 is carried within the catheter 5 and is ejected at the time of deployment such that it self-expands to a contour generally larger than that in its stored state, and large enough to exert an outward elastic
25 retaining and supporting force against the wall of the vessel in which it is placed. The illustrated stent 10 is shown as a simple helical winding of diameter larger than the intended vessel inner diameter. Such a stent may be formed of a superelastic material that springs back to a greatly expanded shape, or may be formed of a shape memory alloy (SMA) which reassumes a pre-set larger shape as microstructure of its material
30 composition changes state. Suitable shape memory alloys include Nitinol and various

titanium alloys, for which the properties may be varied by suitable selection of the alloy components in a manner known in the art. In general, the shape of the stent is subject to two constraints, namely that it be self-expanding to form a self-anchoring venous stent when deployed, and that it contain an ablation portion, such as an exposed conductive portion, effective to ablate a blocking line in the vessel at or near the os. Preferably this conductive loop or ablation portion, discussed further below, is located at the proximal end, so that any extreme current or heating of the stent is restricted to a small initial length that does not contribute substantially to the overall function of supporting the vessel wall. The proximal location assures that the lesion formed by the stent will block substantially all trigger signals originating in the vein. The stent alloy or material may be selected to be compatible with operation at the ablation temperature, or the exposed ablation band may be implemented with a hybrid structure, by a construction with a suitable conductor separately carried by the self-expanding stent.

As shown in Figure 2, the illustrated stent 10 includes a number of circumferential windings 12a, 12b, 12c.... At least one winding, illustratively winding 12b, is located close to the proximal end of the stent and has an exposed conductive surface that directly contacts the surrounding inner wall of the vessel. Other windings illustratively 12a, 12c have insulating material 14 thereabout. Delivery of the stent from the catheter tip and its deployment in the pulmonary vein may be accomplished by any of a number of known mechanisms, such as by having the stent tightly wound or compacted within an outer sheath that is withdrawn to release the stent for radial expansion; or by having a cylindrical sleeve and an inner plunger within the catheter tip that pushes the stent outwardly therefrom, or grips the stent distal end and pulls it, to deploy it in the vessel. However, whichever ejection or deployment mechanism is utilized, the tip assembly further includes a means for energizing the stent after such deployment.

As further shown in Figure 2, the proximal end of stent 10 when initially deployed from the tip remains close to or within the catheter. In accordance with a principal aspect of this embodiment of the present invention, this end of the stent is electrically connected to an energy delivery line 18 such as an electrically conductive lead, wire or cable that is energized with a suitable RF or other electrical signal. Continuing with a description of

Figure 1, after the stent is deployed near the ostium of the pulmonary vein, this RF line is activated so that the conductive loop 12b (Figure 2) contacting the vessel interior ablates a blocking lesion in an arc around the inner vessel wall along its line of contact between the vessel wall and the exposed stent. The stent is then disconnected from the catheter so that it resides as a separate stent remaining in the pulmonary vessel, and the catheter is withdrawn from the patient.

In general, the manner of forming an electrical connection between the energy supply line 18 and the stent 10 may take several forms. One suitable mechanism for connecting the stent and delivery line is to form a fusible link at the junction of the delivery line 18 and the stent 10, with the link having a composition and size that is intended to pass sufficient current for ablating the inner vessel wall, yet to fuse when a short pulse of higher current is applied, thereby causing the two conductive structures to separate. A ground shunt wire within the catheter may be provided to momentarily contact a conductor and cause the link to fuse. Another suitable method of connecting the energy line to the stent is to provide a conductive cylinder or piston at the catheter distal tip which operates as the stent ejection mechanism and which is also connected to the energy supply line. This mechanism captures the proximal end of the stent between or against a structure such as the surrounding sleeve or catheter body (not numbered). The stent then remains electrically connected to the energy source so long as a portion of the distal stent end has not been fully ejected from the catheter. Once the ablation energy has been applied, the cylinder or piston is then advanced (or retracted) to the end of its travel to release the stent entirely and electrically disconnect it. Still a third suitable method of connection is to provide a pigtail connection that may be broken off or severed, or is attached by conductive adhesive and may be peeled back by a simple low-tension pull. Conductive gel or the like may also be used to effect or improve a temporary conductive coupling between parts of the tip assembly and the stent.

The stent of Figure 2 is a simple open helical coil. However, applicant contemplates that other forms of expandable or self-expanding stent may be employed or adapted for the intended application. The shape of the stent may take any of a number of forms, such as a serpentine wire or ribbon configuration, a bent-corner zig-zag

configuration or other coil configuration compatible with SMA or superelastic expansion or re-shaping for deployment. Thus, for example, a stent may be formed in a closed loop that extends in a narrow zigzag band around a generally circumferential direction as illustrated in Figure 3 in a side view. As shown in that Figure, the stent 20 is formed of a single strand of material which zig-zags back and forth over a width W in the axial direction, and forms a closed loop so as to provide a springy structure which self-expands to a much greater diameter and provides radial support of the vessel wall. In this case, the entire stent length may operate as an exposed conductor ablation wire. As with the embodiment of Figure 2, a superelastic or shape memory alloy material may be employed to form the stent and cause it to self-expand without requiring a balloon or other external source of pressure or mechanical expansion force.

In general, applicant contemplates that the self-expanding stent have sufficient outwardly directed force to resist the elastic recoil of the vein, which is rather small in magnitude, and to guard against stenotic narrowing of the vessel following ablation. The ablative operation of the stent may be essentially a unipolar ablation, and carried out by applying RF energy to the conductive contacting portion of the stent while, for example, providing a return path through a large area surface electrode or ground electrode located on the patient's skin. The ground electrode may be positioned so as to minimize the possibility of current paths extending through the heart itself. Alternatively, the ablating loop may carry multiple electrode elements to allow either unipolar or bipolar RF energy delivery as well as cardiac signal recording.

Figure 4 shows a third embodiment 30 of the pulmonary vein stent of the present invention configured for delivery by a catheter 5. In this embodiment, the proximal portion of the stent 30 includes a loop 34 that is substantially larger in diameter than the pulmonary vein and remains outside the vein, and a distal portion 32 that extends into and anchors within the vein. In this embodiment, the proximal portion may be the ablation portion, deployed to lie against the endocardial surface of the posterior left atrium and ablate a circumferential lesion outside of and entirely surrounding the pulmonary vein os.

Figures 4A-4C illustrate installation and operation of this stent with one delivery catheter 5. As illustrated, the stent 30 may be delivered by a catheter delivery system wherein an axially-moved member 37 engages the distal end 32 of the stent and advances to pull the coiled stent into the pulmonary vein, while the proximal loop 34 remains connected via a catheter 5 to a source of ablation energy. This tensile pulling may reduce the diameter of the coils 32, allowing clearance for the stent to travel up the pulmonary vein to an anchoring site. As shown in Figure 4B, the puller is then disengaged and may be retracted into the catheter, while the proximal loop 34 elastically bears against the endocardial surface of the posterior left atrium along a path that substantially surrounds the os, while remaining connected to the ablation energy source by connecting portion 38. Once the blocking lesion is formed, the stent is entirely disconnected and left in place, as shown in Figure 4C.

In this embodiment, preferably the proximal loop 34 is configured to apply the ablation energy, while the distal portion 32 operates as a stent to anchor the assembly and prevent stenosis. The ablation lesion, corresponding to position of the proximal loop or loops 34 in Figure 4C is thus entirely outside the pulmonary vein. In alternate embodiments, both the distal and proximal portions may be energized. A stent shaped as in Figure 4 may also be constructed, or used, as a pulmonary vein stent without ablation, to assure patency of the vessel after treatment or ablation has been effected with some other or a conventional ablation catheter. Such a stent may be implemented with spaced-apart loops rather than a helical structure, and may include longitudinal struts to provide further wall support and prevent intercoil recoil, as shown in Figure 4D.

In addition to the illustrated forms of stent, various other forms of stent either proposed in the literature or existing as commercial products may be readily adapted for the practice of the present invention, and in this case the electrical driving current or other ablation energy and the delivery mechanisms may be modified as appropriate for allowing deployment while connected, and then severing the catheter ablation energy connection. Stents such as flexstent-type, wallstent-type, Gianturco-type stents or Palmaz-type stents may be constructed and configured for the practice of the invention by applying insulation over the distal ends and providing an energy connection in the tip assembly. An expansion

balloon may be further provided if needed, dimensions permitting, and the stent itself may be configured with projecting barbs, or treated to assure effective anchoring.

Known RF and other ablation consoles may be adjusted or programmed to apply suitable levels of RF ablation or treatment energy through the exposed portion of the stent.

5 When adapting such existing stents, whether proposed or commercially available, one may change their mechanical properties, and the relative widths or form, to achieve suitable ablation contact areas for use with RF consoles in the practice of the invention, and impedance matching elements may be employed to more closely achieve the desired circuit characteristics for the described ablation procedure. Moreover, it will be appreciated that
10 the conductive portions (12b in Figure 2, 34 in Figure 4 or the entire stent in Figure 3) need not entirely circumscribe the vessel, but are preferably to extend substantially entirely around a full arc and define a blocking lesion of a contour that effectively isolates the distal vessel wall from conduction to and across the ostium into the atrial wall. In this regard, the spiral configuration of the stent shown in Figure 2 may not entirely disconnect the
15 vessel from the cardiac wall, but may leave a narrow region between successive turns in which, although signals may still be propagated, the length and geometry of the unblocked region effectively prevents trigger signal leakage to the heart. The embodiment of Figure 3 on the other hand forms a completely circumferential blocking lesion, and that of Figure 4 may employ partial or multiple turns in the enlarged initial winding 34 to achieve either
20 form of such blocking lesion. The latter stent and its delivery catheter may also be configured so that the ablation loop 34 detaches from the distal installed stent portion 32 and is simply retracted into the catheter following ablation. This embodiment may be viewed as a specialized ablation catheter similar to the ablation catheter of the above mentioned United States patent application, having an ablation electrode winding that
25 extends in a broad loop or arc in a plane generally transverse or perpendicular to the axis of the catheter, and with a pulmonary vein stent structure further integrated with the ablation electrode.

One skilled in the art will appreciate further features and advantages of the invention based on the above-described embodiments. Accordingly, the invention is not to
30 be limited by what has been particularly shown and described, but will be seen to include

further variations, modifications and adaptations within its scope, as defined by the claims appended hereto and equivalents thereof. All publications and references cited herein are expressly incorporated herein by reference in their entirety.

What is claimed is:

CLAIMS:

1. A catheter insertable device comprising

a self-expanding stent configured to lodge in a pulmonary vein proximate to the ostium thereof to provide circumferential support of said vein,

said stent including an ablation region along at least a portion its length for surface contact with the pulmonary vein and said ablation region subtending at least a substantially complete circumferential band, whereby application of energy to the stent ablates a path effective to block signals generated within the vein from passing the ostium.

2. The device of claim 1, wherein said ablation region comprises a winding at the proximal end of said stent.

3. The device of claim 2, wherein said stent includes a proximal portion having a diameter greater than the pulmonary vein, and a distal portion having a diameter for seating within the pulmonary vein, said proximal portion including said ablation region and being adapted to bear against an endocardial surface of the posterior left atrium to ablate a blocking lesion outside the pulmonary vein.

4. A catheter device comprising

an elongated catheter body extending to tip assembly for delivering a stent to a position in a vessel

a stent carried in said tip assembly, the stent being self-expanding and configured to lodge in a pulmonary vein proximate to the ostium thereof, and wherein the stent includes a first region along its length for ablative surface contact with the pulmonary vein, said first region subtending a substantially complete circumference of the pulmonary vein interior wall, whereby application of energy to the stent ablates a circumferential path effective to block signals generated within the vein from conduction across the ostium.

5. The catheter device of claim 4, wherein the catheter includes an energy delivery line extending to said tip assembly, and means for releasably connecting the energy delivery line to the stent.

5 6. The catheter device of claim 5, wherein said means for releasably connecting includes a fusible link.

7. The catheter device of claim 6, wherein said means for releasably connecting includes a mechanical linkage.

10 8. A system for treating atrial fibrillation comprising
a delivery catheter
a stent carried by the catheter for delivery and placement to a tissue region proximate to the tip of the catheter, said stent being sized and configured for stenting a pulmonary vein and wherein the stent includes a conductive portion extending around a
15 loop for bearing against and conductively contacting surrounding tissue when the stent is deployed in said vein, and

wherein the delivery catheter includes
an energy supply line extending to the distal end of the catheter and
20 means for temporarily connecting the energy supply line to the stent when the stent is deployed in the vein so as to ablate a tissue region and block conduction from the venous wall to the heart, and thereafter disconnect the energy supply from the stent leaving the stent in position to prevent stenosis.

25 9. The system of claim 8, wherein the conductive portion lies in a proximal region of the stent and is configured to bear against and ablate a blocking lesion in posterior endocardial wall of the atrium.

10. A method of treating atrial fibrillation, such method comprising the steps of
placing a stent in a pulmonary vein, and
energizing at least a portion of the stent to ablate a blocking line proximate
the os.

5

11. The method of claim 10, wherein said portion is positioned to ablate a
circumferential blocking lesion of the pulmonary vein wall.

12. The method of claim 10, wherein said portion is positioned to ablate a blocking
lesion in posterior left atrium endocardial surface tissue substantially surrounding the os.

10

13. A method of treating a pulmonary vein of a patient, such method comprising the
steps of

15 providing a stent having a proximal portion and having a distal portion, the
distal portion having a size and configuration to anchor in and support the wall of a
pulmonary vein, and the proximal portion having a diameter larger than the distal portion,
wherein the stent is configured for catheter delivery in a compact state and expansion to
said size and configuration such that when released from the catheter the proximal portion
contacts the vessel os or the wall of the atrium while the distal portion prevents stenosis of
20 the pulmonary vein.


20

14. The method of claim 13, further comprising the step of connecting an ablation
source to the proximal portion to ablate a substantially circumferential blocking lesion and
block conduction of a trigger signal from the pulmonary vein to the atrium.

25

30

1/5

*FIG. 1*

2/5








FIG. 1A

3/5

**FIG. 2****FIG. 3**

4/5



5 / 5




FIG. 4A




FIG. 4B




FIG. 4C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/24835

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61B 18/18

US CL :606/002

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 606/002

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, 5,507,743 A (Edwards et al.) 16 April 1996. See entire document.	1-14
Y	US, 5,573,531 A (Gregory) 12 November 1996. See entire document.	1-3
Y	US, 5,593,405 A (Osypka) 14 January 1997. See entire document.	4-14
Y,P	US, 6,012,457 A (Lesh) 11 January 2000. See entire document.	1-14

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 17 NOVEMBER 2000	Date of mailing of the international search report 28 DEC 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer AHMED M. FARAH Telephone No. (703) 308- 3549